^
    Back
    Association details:
    Biomarker:Lewis-Y expression
    Cancer:Non Small Cell Lung Cancer
    Drug:SGN-15 (Topoisomerase II inhibitor, Lewis Y-related antigen-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Lung Cancer
    Title:

    A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma

    Excerpt:
    Sixty-two patients with recurrent or metastatic NSCLC expressing Le(y)...SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients.
    Secondary therapy:
    docetaxel
    DOI:
    10.1016/j.lungcan.2006.05.020